Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Bronchodilators Market Evolve in Terms of Growth and Size by 2029?

The market for bronchodilators has experienced significant growth in recent years. From 2024 to 2025, it is projected to rise from $32.93 billion to $35.31 billion, reflecting a compound annual growth rate (CAGR) of 7.2% Factors contributing to this upturn in the historical period include a growing elderly population, an increase in asthma cases, enhanced funding from governmental organizations, a surge in the ageing demographic, and a rise in global air pollution.

Over the upcoming years, the bronchodilators market is predicted to experience substantial growth, increasing to “$45.14 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. This predicted increase during the forecast period is due to several factors including the rising incidence of COPD, heightened awareness about treatments for lung diseases, enhanced research and development activities, growing cases of pulmonary disorders, an uptick in disposable income, and escalating smoking rates. The prediction period also sees trends like advanced clinical research and innovative strategic approaches, increased technological advancements, a high prevalence of lung diseases such as COPD and asthma, the introduction of new products, and a surge in the number of acute respiratory infection patients.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13816&type=smp

What factors are expected to fuel Bronchodilators market growth in the coming years?

The growth of the bronchodilator market is forecasted to be accelerated by the rising occurrence of chronic obstructive pulmonary disease (COPD). This progressive lung disorder is identified by persistent inflammation of the airways and restriction or hindrance of airflow. Bronchodilators, which relax the muscles surrounding the airways, making it easier to breathe, are commonly used in the treatment of COPD. For example, a report by the Scottish Public Health Observatory, under the direction of Public Health Scotland, an UK-based health center focused on population, showed an uptick in COPD rates as the effects of COVID-19 started to diminish in March 2023. The male rate rose from 83.2 to 97.6 cases per 100,000, while the female rate experienced an increase from 72.6 to 97.3. Therefore, the climbing incidence of COPD is spurring the expansion of the bronchodilator market.

The bronchodilators market covered in this report is segmented –

1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types

2) By Route of Administration: Oral, Nasal (Inhalation), Injectable

3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications

4) By End-User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Beta-Adrenergic Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs)

2) By Anticholinergic Bronchodilators: Short-Acting Anticholinergics, Long-Acting Anticholinergics

3) By Xanthine Derivatives: Theophylline, Aminophylline

4) By Other Types: Leukotriene Receptor Antagonists, Combination Therapies

What Notable Trends Are Shaping The Direction Of The Bronchodilators Market?

Prominent corporations in the bronchodilator market are introducing innovative product offerings such as triple-drug combinations with fixed doses to better accommodate patient needs. The fixed-dose triple-drug combination is a medicinal product that consolidates three active ingredients in one formula, where each ingredient’s dose is predefined. For example, in January 2023, DIFIZMA, a triple-drug fixed-dose bronchodilator, was introduced by Lupin, a pharmaceutical company based out of India. This bronchodilator, combining indacaterol, glycopyrronium, and mometasone, is used for asthma management. It is dispensed as a dry powder for inhalation. DIFIZMA, which is recognized by the Drug Controller General of India (DCGI), is the sole approved fixed-dose combination for the treatment of uncontrolled asthma, as it enhances lung function, provides superior symptom control and reduces exacerbations.

What Are The Most Active Companies In The Bronchodilators Market Today?

Major companies operating in the bronchodilators market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Thermo Fisher Scientific, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Siemens Healthcare GmbH, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Quest Diagnostics Incorporated., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Vectura Group Limited, Foundation Medicine Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Kissei Pharmaceutical Co.Ltd., Mitsubishi Tanabe Pharma, Theron Pharmaceuticals, Viatris Inc.

https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report

Which Regional Markets Are Attracting The Most Investment In Bronchodilators?

North America was the largest region in the bronchodilators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13816&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model